Maria Brouch

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

S. Trudel, P. Richardson, N. Callander, 2021, Future oncology.

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Trudel, P. Richardson, H. Nahi, 2020 .